Literature DB >> 11580232

IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit.

Z Lazarova1, C Yee, J Lazar, K B Yancey.   

Abstract

Anti-epiligrin cicatricial pemphigoid (AECP) is a mucosal-predominant, subepithelial blistering disease characterized by IgG anti-basement membrane autoantibodies to laminin 5 (alpha3beta3gamma2). This and prior studies found that autoantibodies from most patients recognize the alpha-subunit of this laminin isoform. Accordingly, sera from 10 representative patients were tested against prokaryotic recombinants of this polypeptide in epitope mapping studies. cDNAs spanning the full length of the alpha-subunit were generated by PCR, directionally cloned into the pGEX-4T-3 vector, and expressed as glutathione-S-transferase fusion proteins of appropriate size and immunoreactivity. Sera from 9 of 10 AECP patients immunoblotted fusion proteins corresponding to subdomains G2, G3, G4, and G5 at the carboxyl terminus of the laminin 5 alpha-subunit. Serum from 1 patient (and that from normal volunteers) showed no reactivity to any fusion proteins; no sera bound recombinant glutathione-S-transferase alone. Immunoadsorption of patient sera with fusion proteins corresponding to the G domain substantially reduced basement membrane autoantibody titers. IgG from patients with this form of cicatricial pemphigoid recognize the portion of laminin 5 thought to play a key role in promoting keratinocyte adhesion to epidermal basement membrane. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580232     DOI: 10.1006/clim.2001.5091

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  Laminin 332 deposition is diminished in irradiated skin in an animal model of combined radiation and wound skin injury.

Authors:  M M Jourdan; A Lopez; E B Olasz; N E Duncan; M Demara; W Kittipongdaja; B L Fish; M Mäder; A Schock; N V Morrow; V A Semenenko; J E Baker; J E Moulder; Z Lazarova
Journal:  Radiat Res       Date:  2011-08-19       Impact factor: 2.841

2.  Gene expression profiling of laminin α3-blocked keratinocytes reveals an immune-independent mechanism of blistering.

Authors:  Lei Bao; Bethany E Perez White; Jing Li; Payal M Patel; Kyle T Amber
Journal:  Exp Dermatol       Date:  2021-11-26       Impact factor: 4.511

3.  Mucous membranepemphigoid in two half-sisters. The potential roles of autoantibodies to β4 integrin subunits and HLA-DQβ1*0301.

Authors:  Diogo Fabris Rabelo; Tegan Nguyen; Brooke Ann Caufield; Abdul Razzaque Ahmed
Journal:  J Dermatol Case Rep       Date:  2014-03-31

4.  Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid.

Authors:  Stephanie Goletz; Federica Giurdanella; Maike M Holtsche; Miranda Nijenhuis; Barbara Horvath; Gilles F H Diercks; Detlef Zillikens; Takashi Hashimoto; Enno Schmidt; Hendri H Pas
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

Review 5.  Molecular diagnosis in autoimmune skin blistering conditions.

Authors:  J V Otten; T Hashimoto; M Hertl; A S Payne; C Sitaru
Journal:  Curr Mol Med       Date:  2014-01       Impact factor: 2.222

6.  Gentamicin Induces Laminin 332 and Improves Wound Healing in Junctional Epidermolysis Bullosa Patients with Nonsense Mutations.

Authors:  Andrew Kwong; Jon Cogan; Yingping Hou; Richard Antaya; Michelle Hao; Gene Kim; Vadim Lincoln; Qiuyang Chen; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2020-03-17       Impact factor: 11.454

7.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.